Pfizer Didn't Get Smaller by Accident. It Was Strip-Mining for a Higher Multiple.

On a Friday in February 2013, Pfizer sold the world its pet-medicine business. Zoetis priced its IPO, raised $2.2 billion, and jumped 19% on day one to $35.01.³ Pfizer kept the controlling block — roughly 83% — and unwound it months later in a separate exchange offer.³ Six years on, it folded its consumer cabinet of Advil and ChapStick into a venture with GSK and booked an $8.1 billion pre-tax gain.⁷ A year after that, it shipped off Lipitor, Lyrica, and Viagra in a single structure and called it Viatris.¹ Each move arrived wrapped in the same sentence about focus. Stack them up and a different shape appears — not a strategy that emerged, but a machine that kept feeding.

The official story is that Pfizer was sharpening itself into a pure innovative-biopharma company — shedding distractions to concentrate on the science. That story is true. It is also the second-most-important thing happening. The first is arithmetic.

The number that wanted the slow businesses gone

A diversified drugmaker carries a problem the market punishes quietly: its parts trade at different multiples. Investors pay a rich price for high-growth patented medicines and a thin one for off-patent pills sliding toward generics. Bolt them together and the whole company gets a blended valuation — the fast engine dragged down by the slow caboose. Pfizer's animal-health unit, its consumer aisle, and above all its established-medicines portfolio were the caboose. The cleanest way to lift the multiple on what remained was not to grow faster. It was to subtract the slow part — and let the residual stub get re-rated as the pure-play growth company it now appeared to be. When Pfizer announced the full Zoetis separation, it said the move 'better positions Pfizer to focus on its core business as an innovative biopharmaceutical company' — and, in the same breath, that the deal would be accretive to Pfizer's earnings per share beginning in 2014.⁴ Both clauses are true. Only one is the reason.

By 2018 the sorting was made explicit. Pfizer reorganized itself into three labeled boxes: an Innovative Medicines business, an off-patent Established Medicines business it named Upjohn, and Consumer Healthcare.⁵ On 2017 numbers, Innovative was expected to be about three-quarters of revenue and Established roughly a quarter.⁵ The company did not call it a holding pen for assets it intended to expel. It did not have to. The org chart was the disposal manifest.

Why Upjohn had to be given away, not sold

Here is the part that turns a clean focus narrative into something more revealing. Upjohn was not junk. Its own SEC filings describe an 'off-patent branded and generic established medicines business' — Lyrica, Lipitor, Norvasc, Celebrex, Viagra, anchored in China and emerging markets, with the Greenstone generics platform bolted on.⁸ These are real brands throwing off real cash. But they were dying brands. In the third quarter of 2019, Upjohn revenue fell 26% operationally, driven by Lyrica losing U.S. exclusivity that July.⁶ For the full year, the unit shrank even setting Lyrica aside.⁶ You cannot sell a declining asset for a premium, and a straight cash sale of a profitable-but-fading business would have triggered a large tax bill on the gain. So Pfizer reached for a structure that solves both problems at once.

On July 29, 2019, Pfizer agreed to combine Upjohn with Mylan in an all-stock Reverse Morris Trust, with Pfizer shareholders set to own 57% of the new company and Mylan holders 43%.² The deal closed November 16, 2020 — months later than the mid-2020 target, slowed in part by regulatory review.¹ And note the precise mechanics: Pfizer the company did not end up owning a stake in Viatris. The shares went directly to Pfizer's stockholders, who received roughly 0.124079 Viatris shares for each Pfizer share and held about 57% on a fully diluted basis at close.¹ The Reverse Morris Trust is the elegant move here — it let Pfizer detach a declining asset, hand it to shareholders tax-free, and keep none of the slow business on its own balance sheet. It could not have sold Upjohn cleanly. So it gave it away in a way that looked like value creation.

Isn't this just good portfolio management?

The honest objection is that none of this is sinister — that focusing a company on its best assets and using a tax-efficient structure to do it is simply competent capital allocation, the kind every advisor would recommend. Fair. There is no scandal in a Reverse Morris Trust, and a slimmer, science-led Pfizer plausibly is a better company than the conglomerate it left behind. But notice what the 'focus' framing conveniently launders. It recasts a defensive maneuver — protecting the multiple of the residual stub from the gravity of declining cash cows — as a confident offensive bet on innovation. The Consumer Healthcare move is the tell: Pfizer didn't even sell that business: it parked it in a JV, kept 32%, and waited years to exit, finally selling its Haleon stake only in March 2025.⁷ That is not the behavior of a company that simply wanted to be rid of distraction. It is the behavior of a company managing the timing and tax treatment of an exit it had already decided on. Good portfolio management and strip-mining the multiple are not opposites. They are the same act, described by whoever is doing the describing.

Pfizer spent a decade getting smaller on purpose. It sold the pets, parked the painkillers and lozenges, and gave away the off-patent classics — each time narrating the subtraction as a return to the lab. The narration was true enough. But the recurring logic underneath every deal was never really about science. It was about which assets the market would pay a high price to own, and which ones had to be removed so the rest could be re-rated cleanly. Pfizer didn't discover focus. It discovered that the fastest way to look like a growth company is to amputate everything that wasn't one — and to do it in a structure where the cutting looks like a gift.